Oligonucleotide therapeutics: chemistry, delivery and clinical progress. - Wikidata - awgldk - TriplyDB

Oligonucleotide therapeutics: chemistry, delivery and clinical progress.

Oligonucleotide therapeutics: chemistry, delivery and clinical progress.

http://www.wikidata.org/entity/Q38618638

about

The delivery of therapeutic oligonucleotides Splice-switching antisense oligonucleotides as therapeutic drugs Anti-sense oligonucleotide therapies for the treatment of hyperlipidaemia.Non-coding RNAs as drug targets.One-bead coarse-grained model for RNA dynamics.Translational development of splice-modifying antisense oligomers.The chemical evolution of oligonucleotide therapies of clinical utility.Locked Nucleic Acid Gapmers and Conjugates Potently Silence ADAM33, an Asthma-Associated Metalloprotease with Nuclear-Localized mRNA Antisense Oligonucleotide Mediated Splice Correction of a Deep Intronic Mutation in OPA1.Synthesis and antibacterial activity of 5'-tetrachlorophthalimido and 5'-azido 5'-deoxyribonucleosides.Using Genome Sequence to Enable the Design of Medicines and Chemical Probes.Advances at the intersection of chemical biology and medicinal chemistry.Chemistry, mechanism and clinical status of antisense oligonucleotides and duplex RNAs.Quantitative analysis of imetelstat in plasma with LC-MS/MS using solid-phase or hybridization extraction.Stimuli-responsive oligonucleotides in prodrug-based approaches for gene silencing.

P2860

Q37210936-B4F97433-1DDD-4F3F-B370-5A97AAFFE0B3 Q37211004-59411623-C922-48EB-955C-6C38916D7C0B Q38850010-175B02BF-8667-4014-9BFA-6FB4D3B1D51E Q38904908-5607D9B6-45A4-416C-9626-FEA59228E916 Q38986192-53D78127-39D0-4F3F-9273-38D35391F902 Q38996657-9D7CD1AE-C82F-4930-920B-3B08B0CF2431 Q39154511-ED046E55-AD93-4D63-9E3E-ED6E61DC113A Q41520047-4127898F-C401-42DE-820D-D55E9ACA99CA Q41787118-1FF8393C-57B9-4A56-8A3D-D042713183D1 Q46163154-EB09A888-4482-45C7-806F-2877C64606B3 Q48263612-A602838B-E4AD-46E4-B76A-38282A4B51BA Q48319675-3A0CDC30-4406-44FF-B3CE-911E992FF0E7 Q48569299-72E171E7-4193-487A-910E-6EDE6A927334 Q50075192-12F3F306-53AE-452D-B34F-100244580BB7 Q51742560-6CCC3AC0-195D-4440-A0F8-A7A0931BC5CE

P2860

Oligonucleotide therapeutics: chemistry, delivery and clinical progress.

http://www.wikidata.org/entity/Q38618638

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年学术文章

@wuu

2015年学术文章

@zh-cn

2015年学术文章

@zh-hans

2015年学术文章

@zh-my

2015年学术文章

@zh-sg

2015年學術文章

@yue

2015年學術文章

@zh

2015年學術文章

@zh-hant

name

Oligonucleotide therapeutics: chemistry, delivery and clinical progress.

@en

type

label

Oligonucleotide therapeutics: chemistry, delivery and clinical progress.

@en

prefLabel

Oligonucleotide therapeutics: chemistry, delivery and clinical progress.

@en

P1433

Q38618638-00E561F0-1532-4108-B05D-3A092245E019

P1476

Q38618638-10D5228F-A575-4C6F-9ACA-B41A453B27B5

P2093

Q38618638-4C78D324-566B-4E83-B2A4-BF245FFDA3F8

P2860

Q38618638-0461A73D-9BEA-4196-AE64-17F9F0ED8AD6

Q38618638-04B3D3C4-8542-4E15-9F2C-C528CB271513

Q38618638-05C91DF5-4751-4E0F-963F-84903F19CF65

Q38618638-06457B11-5436-4948-B58A-6D19BF1F1E60

Q38618638-0752B7F4-020A-4010-9AB7-882BE62FBC58

Q38618638-096E628B-517B-498D-8CE5-B026086917D3

Q38618638-0B3F8872-B784-43BC-A9BC-1C6C06F99681

Q38618638-0E7D8225-69E5-46E2-A077-A3CB5060D880

Q38618638-112D3442-46B5-4148-85DA-374F1C008403

Q38618638-1238F750-27ED-4906-B3EA-509D65DF554A

P304

Q38618638-3FA6CB10-813D-4850-9FD4-E0A9C473277C

P31

Q38618638-1635622E-E2AE-45CE-BA1A-68F0FCB9AB29

P356

Q38618638-D593FA8D-BB0B-45D7-BCAE-1AD686A608B0

P433

Q38618638-58B6495E-22C8-4A39-A402-E63F529AB467

P478

Q38618638-8B0459A0-7D32-4034-9AFC-499150A3878A

P50

Q38618638-E9C569F4-CEE8-4924-84B0-B869A7E52C10

P577

Q38618638-F5AEA47F-12BA-4FDD-8F29-48BCA93858AE

P698

Q38618638-8617B9C3-B431-4F48-995B-47733023C1E3

P356

P1433

Future Medicinal Chemistry

P1476

Oligonucleotide therapeutics: chemistry, delivery and clinical progress.

@en

P2093

Vivek K Sharma

http://www.w3.org/2001/XMLSchema#string

P2860

MODIFIED OLIGONUCLEOTIDES: Synthesis and Strategy for Users

A Programmable Dual-RNA-Guided DNA Endonuclease in Adaptive Bacterial Immunity

Advances in CRISPR-Cas9 genome engineering: lessons learned from RNA interference

Crystal structure of double helical hexitol nucleic acids

Direct observation of a cytosine analogue that forms five hydrogen bonds to guanosine: guanidino G-clamp

NMR structure of an -L-LNA:RNA hybrid: structural implications for RNase H recognition

The solution structure of double helical arabino nucleic acids (ANA and 2'F-ANA): effect of arabinoses in duplex-hairpin interconversion

Synthesis, Improved Antisense Activity and Structural Rationale for the Divergent RNA Affinities of 3′-Fluoro Hexitol Nucleic Acid (FHNA and Ara-FHNA) Modified Oligonucleotides

Preclinical and clinical development of siRNA-based therapeutics

Dacarbazine with or without oblimersen (a Bcl-2 antisense oligonucleotide) in chemotherapy-naive patients with advanced melanoma and low-normal serum lactate dehydrogenase: 'The AGENDA trial'

P304

2221-2242

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.4155/FMC.15.144

http://www.w3.org/2001/XMLSchema#string

P433

16

http://www.w3.org/2001/XMLSchema#string

P478

7

http://www.w3.org/2001/XMLSchema#string

P50

Jonathan K Watts

P577

2015-10-29T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26510815

http://www.w3.org/2001/XMLSchema#string